Medical device company CooperCompanies has signed a binding agreement to buy Cook Medical’s Reproductive Health business in an $875m deal.

Under the terms of the deal, the company will pay $675m at the time of closing and a further $200m in four annual instalments of $50m each.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The Reproductive Health business of Cook Medical manufactures minimally invasive medical devices for fertility, obstetrics, gynaecology, in vitro fertilisation (IVF) and assisted reproductive technology (ART). 

Cook Medical also developed the first needle specifically for use in IVF treatment.

CooperCompanies operates through two business units, CooperVision and CooperSurgical, and offers a range of products and services for women’s health and vision care.

Cooper expects the acquisition of Cook Medical’s Reproductive Health business to help boost CooperSurgical’s international fertility footprint, as well as its medical device portfolio.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

CooperCompanies president and CEO Al White said: “We’re improving our international fertility footprint, especially within the Asia-Pacific region, and adding highly synergistic and respected labour and delivery devices to our ObGyn portfolio.

“These high-quality products will integrate seamlessly into our business and support CooperSurgical’s vision of a world with healthy women, babies and families.”

The deal is subject to regulatory approvals and local consultation obligations.

For a two-year transition period, Cook will continue to produce products for CooperSurgical and will also increase its production capacity to keep up with growth upon completion of the transaction.

Last November, CooperCompanies agreed to acquire Generate Life Sciences for approximately $1.6bn.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact